Investment
Features
FeesSafety
Academy
More
Pluang+

Compare uniQure N.V. Ordinary Shares (QURE) vs SOLAI Limited (SLAI) Price & Performance

uniQure N.V. Ordinary SharesTrade
SOLAI LimitedTrade

Price performance (Past 24H)

Key statistics

uniQure N.V. Ordinary Shares vs SOLAI Limited — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: uniQure N.V. Ordinary Shares is the larger of the two by market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and SOLAI Limited for 42 Days on average.

QURESLAI
Market Cap
$1.48B$880.09M
Volume
2,488,780122,720
Sector
HealthTechnology
52-Week High
$70.59$21.63
52-Week Low
$9.03$2.74
Typical Hold Time
0 Days42 Days
Enterprise Value
$728.62M$879.73M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

uniQure N.V. Ordinary Shares

No Aura AI signal available yet.

SOLAI Limited

SOLAI Limited (SLAI) trades at $3.72 with no recent price movement, showing a mixed technical picture despite a bullish signal from indicators. The company faces severe financial distress with negative gross and net income margins, though it recently beat Q2 2025 EPS expectations. Recent developments include an extraordinary general meeting and a NYSE delisting notice, creating significant uncertainty for investors.

The outlook remains highly speculative with substantial execution and regulatory risks. While technical indicators suggest potential upside, fundamental weaknesses and delisting proceedings present clear downside risks. Investors should approach with caution given the company's negative profitability and ongoing corporate challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QURE
100% Buy0% Sell
Avg holding period · 0 Days
SLAI

No sentiment data available yet.

About uniQure N.V. Ordinary Shares

uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.

Read more on QURE →

About SOLAI Limited

SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.

Read more on SLAI →